In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer

21st April 2026 Uncategorised 0

After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect Welireg surprisingly failed to ignite hope as a first-line treatment.

More: In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
Source: fierce